导师姓名： 薛蔚 专业代码： 100210
性别： 男 专业名称： 外科学
培养单位： 附属仁济医院 三级学科/
专业领域： 泌尿外
导师类型： 博士生导师 专业学位导师： 兼
联系方式： E-Mail:xuewei@renji.com; uroxuewei@163.comTel:(021)**地址：上海市浦东新区浦建路160号
邮编： 200127 邮箱地址： uroxuewei@163.com

研究方向 (点击浏览详细信息)
泌尿系肿瘤，特别是前列腺肿瘤的基础和临床研究

社会任职
中国医师协会泌尿外科医师分会常委
中国医师协会机器人医师分会委员
上海市医学会泌尿外科分会副主任委员
上海市卫生局泌尿外科临床质控中心专家组委员
《中华外科杂志》、《中华泌尿外科杂志》、《现代泌尿外科杂志》编委

科研项目 项目编号项目名称课题来源起止年月批准经费承担职责
** 内分泌治疗自诱导的CHRM3激活在前列腺癌去势抵抗中的作 国家自然科学基金面上项目 2018-01~2020-12 55万元 课题负责人
SHDC** 肌层浸润性膀胱癌的精准微创治疗 上海申康医院发展中心市级医院新兴前沿技术项目 2016-01~2018-12 80万元 课题负责人
** 端粒失保护在前列腺癌进展转移中的作用和分子机制 国家自然基金面上项目 2016-01~2019-12 57万元 课题负责人
** 转移性前列腺癌基因工程小鼠模型的建立 上海市科委项目 2014-07~2016-09 25万元 课题负责人
PWZxq2014－05 前列腺癌的个性化诊治和分子特征分析 上海市浦东新区卫生系统重点学科群建设 2014-04~2017-03 120万元 课题负责人

学术论文 作者论文标题期刊名出版年卷期页码
Fan L, Wang Y, Chi C, Pan J, Shangguan X, Xin Z, Hu J, Zhou L, Dong B*, Xue W*. （通讯作者） Chromogranin A and neurone-specific enolase variations during the first three months of abiraterone therapy predict outcomes in patients with metastatic castration-resistant prostate cancer. BJU Int. 2017 2017 Aug;120(2):226-232.
Shangguan X, Dong B, Wang Y, Xu F, Shao X, Sha J, Zhu Y, Pan J*, Xue W*. （通讯作者） Management of prostate cancer patients with locally adverse pathologic features after radical prostatectomy: feasibility of active surveillance for cases with Gleason grade 3 + 4 = 7. J Cancer Res Clin Oncol. 2017 2017 Jan;143(1):123-129.
Xu F, Gao Y, Wang Y, Pan J, Sha J, Shao X, Kang X, Qin J, James You M, Huang Y, Dong B*, Xue W*. （通讯作者） Decreased TSPAN1 promotes prostate cancer progression and is a marker for early biochemical recurrence after radical prostatectomy. Oncotarget. 2017 2016 Sep 27;7(39):63294-63305.
Wang Y, Xie S, Shangguan X, Pan J, Zhu Y, Xin Z, Xu F, Shao X, Fan L, Sha J, Liu Q, Dong B*, Xue W*. （通讯作者） Prostate transitional zone volume-based nomogram for predicting prostate cancer and high progression prostate cancer in a real-world population. J Cancer Res Clin Oncol. 2017 2017 Jul;143(7):1157-1166.
Li N#, Xue W# （共同第一作者）, Yuan H#, Dong B, Ding Y, Liu Y, Jiang M, Kan S, Sun T, Ren J, Pan Q, Li X, Zhang P, Hu G, Wang Y, Wang X, Li Q, Qin J*. AKT-mediated Stabilization of WHSC1 Promotes Prostate Cancer Metastasis. J Clin Invest. 2017 2017 Apr 3;127(4):1284-1302.
Shao X, Pan J, Wang Y, Zhu Y, Xu F, Shangguan X, Dong B, Sha J, Chen N, Chen Z, Wang T, Liu S*, Xue W*. （通讯作者） Evaluation of expressed prostatic secretion and serum using surface-enhanced Raman spectroscopy for the noninvasive detection of prostate cancer, a preliminary study. Nanomedicine. 2017 2017 Apr;13(3):1051-1059.
Chen R#, Xie L#, Xue W#, Ye Z, Ma L, Gao X, Ren S, Wang F, Zhao L, Xu C, Sun Y*; （共同第一作者） Chinese Prostate Cancer Consortium. Development and external multicenter validation of Chinese Prostate Cancer Consortium prostate cancer risk calculator for initial prostate biopsy. Urol Oncol. 2016 2016 May 12. pii: S1078-1439(16)30012-6.
Wang YQ, Zhu YJ, Pan JH, Xu F, Shao XG, Sha JJ, Liu Q, Huang YR, Dong BJ*, Xue W*. （通讯作者） Peripheral monocyte count: an independent diagnostic and prognostic biomarker for prostate cancer - a large Chinese cohort study. Asian J Androl. 2016 2016 Aug 26.
Wang Y, Xu F, Pan J, Zhu Y, Xu F, Shao X, Sha J, Wang Z, Cai Y, Liu Q, Dong B*, Xue W* （通讯作者）, Huang Y Platelet to lymphocyte ratio as an independent prognostic indicator for prostate cancer patients receiving androgen deprivation therapy. BMC Cancer. 2016 2016 May 24;16(1):329.
Wang Y#, Yin W#, Wang Z, Huang J, Pan J, Zhu Y, Xu F, Shao X, Sha J, Cai Y,Liu Q, Dong B*, Xue W* （通讯作者）, Huang Y. Pretreatment Plasma Fibrinogen As an Independent Prognostic Indicator of Prostate Cancer Patients Treated With Androgen Deprivation Therapy. Prostate Cancer Prostatic Dis. Prostate Cancer Prostatic Dis. 2016 2016 Jun;19(2):209-15.
Huang J#, Dahl DM, Dong L, Liu Q, Cornejo K, Wang Q, Wu S, Feldman AS, Huang Y, Xue W* （通讯作者）, Wu CL*. Preoperative Neutrophil-to-Lymphocyte Ratio and Neutrophilia Are Independent Predictors of Recurrence in Patients with Localized Papillary Renal Cell Carcinoma. Biomed Res Int. 2015 2015:891045.
Xuan H#, Xue W* （通讯作者）, Pan J, Sha J, Dong B, Huang Y. Downregulation of miR-221, -30d, and -15a contributes to pathogenesis of prostate cancer by targeting Bmi-1. Biochemistry (Mosc). 2015 80(3):276-83.
Dong B#, Minze LJ, Xue W* （通讯作者）, Chen W*. Molecular insights into the development of T cell-based immunotherapy for prostate cancer. Expert Rev Clin Immunol. 2014 10(11):1547-57.
Pan J#, Xue W# （共同第一作者）, Sha J, Yang H, Xu F, Xuan H, Li D, Huang Y*. Incidental prostate cancer at the time of cystectomy: the incidence and clinicopathological features in Chinese patients. PLoS One. 2014 9(4):e94490.
Xue W#, Xie Y#, Wang Q, Xu W, Mou S*, Ni Z. Diagnostic performance of urinary kidney injury molecule-1 and neutrophil gelatinase-associated lipocalin for acute kidney injury in an obstructive nephropathy patient. Nephrology (Carlton). 2014 19(4):186-94.
Pan J#, Xue W# （共同第一作者）, Xia L, Zhong H, Zhu Y, Du Z, Chen Q*, Huang Y. Ureteroscopic lithotripsy in Trendelenburg position for proximal ureteral calculi: a prospective, randomized, comparative study. Int Urol Nephrol. 2014 46(10):1895-901.
Xie Y#, Xue W* （通讯作者）, Shao X, Che X, Xu W, Ni Z, Mou S*. Analysis of a urinary biomarker panel for obstructive nephropathy and clinical outcomes. PLoS One. 2014 9(11):e112865.
Jiang C#, Qi C, Sun K, Xia L, Xue W* （通讯作者）, Huang Y. Diagnostic value of N-acetyl-β-D-glucosaminidase for the early prediction of acute kidney injury after percutaneous nephrolithotripsy. Exp Ther Med. 2013 5(1):197-200.
Dong B#, Jia J#, Hu W, Chen Q, Jiang C, Pan J, Huang Y, Xue W* （通讯作者）, Gao H*. Application of 1H NMR metabonomics in predicting renal function recoverability after the relief of obstructive uropathy in adult patients. Clin Biochem. 2013 46(4-5):346-53.
Pan J#, Chen Q, Xue W* （通讯作者）, Chen Y, Xia L, Chen H, Huang Y. RIRS versus mPCNL for single renal stone of 2-3 cm: clinical outcome and cost-effective analysis in Chinese medical setting. Urolithiasis. 2013 41(1):73-8.
Wu B#, Dong B, Xu Y, Zhang Q, Shen J, Chen H, Xue W*. （通讯作者） Economic evaluation of first-line treatments for metastatic renal cell carcinoma: a cost-effectiveness analysis in a health resource-limited setting. PLoS One. 2012 7(3):e32530.
Pan J#, Xue W* （通讯作者）, Chen Q, Chen Y, Chen H, Huang Y. Antifibrotic role of captopril after ureteral injury. Urol Int. 2012 89(4):418-24.
Cao M#, Zhao L#, Chen H, Xue W* （通讯作者）, Lin D*. NMR-based metabolomic analysis of human bladder cancer. Anal Sci. 2012 28(5):451-6.
Xue W#, Pacik D, Boellaard W, Breda A, Botoca M, Rassweiler J, Van Cleynenbreugel B, de la Rosette J*; CROES PCNL Study Group. Management of single large nonstaghorn renal stones in the CROES PCNL global study. J Urol. 2012 187(4):1293-7.